DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
semaglutide (Ozempic) to semaglutide (Wegovy). Dose mapping, washout, expected side effects, and the editorial verdict.
Patients on Ozempic for off-label weight loss often switch to Wegovy once they get a BMI-based diagnosis that qualifies for the on-label weight-loss formulation. Same molecule (semaglutide), higher approved maintenance dose, and commercial insurance is more likely to authorize Wegovy for obesity than Ozempic.
No washout required. Continue the same weekly cadence and start Wegovy at the matching dose the next scheduled injection day.
For most weight-loss patients who started on Ozempic for cost or supply reasons, switching to Wegovy is administratively cleaner and clinically equivalent at matched doses.
Nausea may return briefly as you titrate above 2 mg, since you are exceeding the Ozempic ceiling. Most patients tolerate it; if nausea is severe at 2.4 mg, prescribers often hold at 1.7 mg.
Wegovy has dedicated weight-loss PA pathways. Commercial plans that excluded Ozempic for weight loss may approve Wegovy at BMI ≥ 30 (or ≥ 27 with comorbidity). Manufacturer NovoCare Direct cash-pay at $499/mo bypasses insurance entirely.
Cash-pay similar (~$1,000+/mo retail without copay card). Commercial coverage usually better for Wegovy due to clearer obesity indication.
Continue Ozempic if you have type 2 diabetes and Wegovy is excluded from your formulary. The diabetes coverage is more predictable.
Editorial summary, not medical advice. Drug switches should be coordinated with your prescriber. Dose conversions reflect typical practice; your prescriber may adjust based on tolerance, comorbidities, or interactions.